Olverembatinib
B Cell Precursor Type Acute Leukemia
First Affiliated Hospital of Zhejiang UniversitySmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
24 Active assets in the B Cell Precursor Type Acute Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Blinatumomab Amgen | Phase 3 | BBB |
Fludarabine National Cancer Institute (NCI) | Phase 2/3 | BB |
Cyclophosphamide Princess Maxima Center for Pediatric Oncology | Phase 2/3 | BB |
Cytosin-Arabinosid Princess Maxima Center for Pediatric Oncology | Phase 2 | B |
METHOTREXATE First Affiliated Hospital of Zhejiang University | Phase 2 | B |
View all 28 →
Same molecule, other indications
Olverembatinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
66 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →